ASCO really offers some great resources. Another fantastic resource that ASCO provides is the People Living With Cancer website. (www.plwc.org) I had the opportunity to meet with several ASCO members who work with advocates, and they are doing some great things.
In regards to cholangio trials that were presented at ASCO, there were few. But I thought I'd link some of the abstracts that I did have the opportunity to see and visit with the main authors. I hope these links work:
Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma.
http://www.asco.org/portal/site/ASCO/me … ctID=33293
Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers.
http://www.asco.org/portal/site/ASCO/me … ctID=36038
SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas.
http://www.asco.org/portal/site/ASCO/me … ctID=35266
What's interesting is the study presented on liver cancer and sorafenib. Liver cancer patients treated with sorafenib experienced a greater overall survival. (median overall survival increased from 7.9 months to 10.7 months) This increase in overall survival was significant enough that sorafenib is being contemplated to be the first line of treatment for liver cancer. However, studies involving sorafenib and cholangio did not see similar benefits. I have a question into one of the doctors asking him to elaborate on this further, as the study on liver cancer is probably very different from the study on cholangio. As soon as I get an answer, I'll update this message thread. In the mean time, here's the study on liver cancer:
Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial)
http://www.asco.org/portal/site/ASCO/me … ctID=32716